Thursday, October 10 2019
Pharmaceutical firm Johnson & Johnson (J&J) is facing renewed pressure from Doctors Without Borders (MSF) to bring down the cost of tuberclosis medicine bedaquiline to scale up the treatment of the drug-resistant strain and bring down the number of deaths recorded annually.
MSF Thursday renewed their push to have the drugs lowered to below Sh100, about half of the current price tag.
Johnson & Johnson Under Pressure To Lower Cost Of TB Drug
pdf — 1.41 MB